Sera Prognostics

Historical price data

Sera Prognostics, operating as 'The Pregnancy Company,' is a public company dedicated to transforming prenatal care through innovative diagnostics. Its core technology is a proteomic biomarker-based test (PreTRM) that identifies a pregnant individual's personalized risk of preterm birth, enabling targeted interventions. The company is commercializing PreTRM in the U.S., supported by clinical data showing its use can reduce severe neonatal morbidity and mortality, and is developing additional products like the LikeMine™ data platform to expand its offerings in women's health.

Proteomic biomarker discovery and validation platform for developing blood-based diagnostic tests focused on pregnancy complications, starting with a signature of two proteins for preterm birth risk prediction.

Faces limited direct competition as the first commercial proteomic test for individualized preterm birth risk. Primary competition is from traditional, less effective screening methods (clinical history, cervical length ultrasound). Maintains differentiation through proprietary biomarkers, robust clinical data (e.g., AVERT PRETERM Trial), and a comprehensive brand strategy focused on the entire pregnancy journey.